TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must undergo definitive local therapy with either breast conserving therapy or mastectomy~* Clinical Stage 0, I or II breast cancer based on examination and/or conventional imaging of mammogram with or without ultrasound. Tumors must be less than 5 cm in size and the patient clinically node negative~* Able to undergo breast MRI~Exclusion Criteria:~* Not pregnant or breastfeeding~* No prior breast MRI for the newly diagnosed carcinoma at the outside hospital~* No prior mantle radiation~* No locally advanced breast cancer~* No diffuse malignant appearing microcalcifications requiring mastectomy~* No known collagen vascular disease~* No previous ipsilateral radiation~* No participants who undergo surgery at an outside institution~* No prior history of breast carcinoma

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI (Type: ACTIVE_COMPARATOR): MRI
- No MRI (Type: NO_INTERVENTION): No MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 3D Printed Oral Stents for Patients with Head and Neck Cancer Receiving Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is dispositioned to receive definitive or adjuvant radiotherapy for treatment of a diagnosed head and neck malignancy.~* Treating radiation oncologist has determined the necessity of an oral stent and a device has been fabricated by dentistry at MD Anderson Cancer Center (MDACC).~* Patient has received pre-treatment imaging which includes the mandibular and maxillary dentition.~* Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.~* Signed study-specific consent form.~Exclusion Criteria:~* No pre-treatment computed tomography (CT) imaging including the maxilla and mandible is available.~* Prior head and neck radiotherapy.~* Severe trismus with an incisal opening of \< 10 mm.~* Inability to comply with the study procedures.~* Patients who have received dental stents fabricated outside of MDACC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3D printed stent+ MDASI-3D Oral Stents Questionnaire (Type: OTHER): Patients wear a customized 3D printed oral stent over 5-10 minutes in the supine position at the time of radiation simulation, before starting radiation therapy, and in the 3rd to 5th week of radiation therapy. Patients may also optionally wear the commercially-made stent called TruGuard at these timepoints. Ancillary Studies (MDASI-3D Oral Stents Questionnaire)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged newborn to 12 years~* Has written or verbal order for insertion of an IV~* Requires peripheral IV therapy (catheter)~* Has an insertion site in the hand, forearm, foot, leg, or head free of deformities, phlebitis, infiltration, dermatitis, burns, lesions or tattoos~* Demonstrates cooperation with a catheter insertion and the study protocol~Exclusion Criteria:~* In the newborn nursery or intensive care units (neonatal or pediatric)~* On patient-controlled analgesia pump~* Patient is anesthetized~* Terminally ill~* Transferred from the operating room less than 8 hours postanasthesia~* Any child the research staff deem unobservable~* The study IV catheter site will be placed below an old infusion site~* The study IV site needs to be immobilized with a splint or other devices~* Has or has had a previous IV catheter related phlebitis or infiltration during current hospitalization~* Will require a power injection for a radiologic procedure during participation in this study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with OptiVein (Type: EXPERIMENTAL): The patient will have an IV catheter placed with the use of OptiVein device.
- Treatment with Vasofix Certo (Type: ACTIVE_COMPARATOR): The patient will have an IV catheter placed with the use of Vasofix Certo device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pain due to cancer or its treatment; Controlled baseline pain; episodes of predictable, treatment related pain every day that are 4/10 in severity or greater, last 10 minutes or longer, or episodes of breakthrough pain not related to cancer treatment, and are responsive to short acting oral opioids such as morphine or hydromorphone; are able to hold a volume of 1.0cc of water under tongue for a 2-minute period; are able to provide written informed consent; are able to fill out the study forms, and are inpatients~Exclusion Criteria:~* Severe underlying respiratory disease such that the investigator is wary about the risk of respiratory failure from modest doses od opioid; prior sensitivity to methadone; currently are being administered methadone; are clinically unstable or have a life expectancy of less than one month making completion of the trial unlikely; and if they do not understand English sufficiently to provide written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Thymoglobulin (ATG) Dose Finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who underwent their first allogeneic transplant for any malignancy and with any cell (bone marrow, peripheral stem cell, cord blood) or donor (matched or mismatched related or unrelated) source.~2. Biopsy-proven, grade II-IV aGVHD following allogeneic hematopoietic stem cell transplantation (HSCT) of any source (bone marrow, peripheral blood or cord blood stem cells). Enrollment may be started prior to results of biopsy in cases of high clinical suspicion for aGVHD.~3. Early steroid-refractory aGVHD. This is defined as any NR or PD after a minimum of 3 days and not more than 1 week of 1 mg/kg/day of methylprednisolone.~4. Ability to sign informed consent.~5. Ability to return for clinical follow-up as specified in the protocol.~6. Inability to taper as defined by patients on \< or = 1 mg/kg/day of methylprednisolone but unable to further taper without resultant increase of acute GVHD stage.~7. Patients with a reflare of a GVHD defined as worsening of 1 stage of acute GVHD in a patient who initially responded.~Exclusion Criteria:~1. Relapsed malignancy.~2. Acute GVHD as a result of a second or subsequent transplant or donor lymphocyte infusion (DLI).~3. Active, uncontrolled infection.~4. Patients who have received any second-line of immunosuppressive treatment for GVHD beyond corticosteroids and calcineurin inhibitors. Topical steroids, oral budesonide and extracorporeal photochemotherapy started at the time of steroids are allowed.~5. Life-threatening infusion reaction or hypersensitivity to any formulation of ATG in the past.~6. Patients who are pregnant or are breast feeding.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High Dose Thymoglobulin (ATG) (Type: EXPERIMENTAL): High Dose Thymoglobulin (ATG): 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
- Low Dose Thymoglobulin (ATG) (Type: EXPERIMENTAL): Low Dose Thymoglobulin (ATG): 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: REduction of Contrast Via DyeVert Used in CTO Procedures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subjects undergoing CTO PCI at each of the participating centers.~2. Contrast volume recorded during CTO PCI~3. Subjects included in the Multicenter Registry of Chronic Total Occlusion Interventions study (Allina IRB approval # 948134-1)~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients undergoing CTO PCI (Type: None): Evaluates the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated CTO PCI. The system allows monitoring and display of contrast volumes that are manually injected during the procedure which will be compared to physician entered contrast usage thresholds during angiographic procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained prior to study entry?~2. Patient has histologically/cytologically proven, non-resectable or metastatic, adenocarcinoma of the pancreas?~3. Progressive disease during adjuvant chemotherapy (or within 6 month after) or progressive disease during or after first line chemotherapy?~4. Former treatment with chemotherapeutic agent containing gemcitabine?~5. Is the age of the patient ≥ 18 years?~6. Is the ECOG performance status 0-1?~7. Is the absolute neutrophil count (ANC) ≥ 1.5 x 109/l?~8. Is the platelet count ≥ 75 x 109/l?~9. Is the total bilirubin ≤1.5 x UNL (upper normal limit)?~10. Patient has normal liver function? (If liver metastases are present, there is no upper limit for ALAT/SPGT/alk phosph)?~11. Creatinine clearance ≥ 30 ml/min~12. Is the patient capable of following the treatment and the plan of evaluation?~Exclusion Criteria:~1. CTC Grade 3 hyperlipidaemia (\>10.34 mmol/l) in spite of treatment~2. Active former or concurrent history of malignant neoplasm, in the last 2 years?~3. Any condition or therapy which, by the investigators opinion, will expose the patient to a risk or will affect the purpose of the clinical trial?~4. Pregnant or breast feeding patient (fertile patients must use contraceptives)?~5. Infections or other serious medical conditions, which can obstruct the patient's possibility of receiving the treatment? (for instance serious heart, metabolic or lung disease)~6. Known hypersensitivity toward one or more of the parts in the treatment?

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase II: Arm A (Type: EXPERIMENTAL): Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B
- Arm B (Type: ACTIVE_COMPARATOR): Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Endoscopic Exploration for Pancreatic Head Mass

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age range 18-80~* Radiographic diagnosis of resectable pancreatic head mass presumed to be pancreatic adenocarcinoma~Exclusion Criteria:~* Inability to obtain informed consent~* Pregnancy~* Intra-abdominal adhesions that preclude endoscopy~* Contraindication to upper endoscopy such as stricture, stenosis of the foregut~* Previous gastric surgery~* Diagnosis of pancreatic body or tail tumor~* History or current diagnosis of gastric ulcer~* Metastatic disease diagnosed by CT, EUS, MRI, or nuclear imaging~* Patient is not a candidate for resection based upon CT, EUS, MRI, or nuclear imaging~* Antiplatelet medication not stopped at least 7 days prior to procedure~* Anticoagulant medication not stopped at least 5 days prior to procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Premature infants between 600 and 900 grams birth weight~* Intubated and on mechanical ventilation~* Sustained (\>= 30 minutes) fraction of inspired oxygen (FiO₂) \>= 0.30 within 8 hours prior to randomization~Exclusion Criteria:~* Mother has prolonged rupture of membranes ≥ 2 weeks~* Culture-proven sepsis~* High grade intraventricular hemorrhage (IVH)~* Congenital heart disease~* Congential anomalies inconsistent with life or likely to confound efficacy or safety endpoints~* FiO₂≥ 0.80 and mean airway pressure (MAP) ≥ 12 cmH2O at day of life (DOL) 3~* FiO₂\< 0.25 at any time between meeting the entry criteria to immediately prior to randomization~* Concomitant use of any other surfactant within the first 48 hours of life~* Prior use of nitric oxide~* Prior use of steroids~* Current participation in any other clinical trial or has received an experimental drug or used an experimental device

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 10 Days
- Healthy Volunteers: f

Study Arms:
- SURFAXIN High Dose (Type: EXPERIMENTAL): SURFAXIN (lucinactant) at 175 mg/kg
- SURFAXIN Low Dose (Type: EXPERIMENTAL): SURFAXIN (lucinactant) at 90 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Sham air using 3.0 mL/kg volume of air

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patient undergoing Fontan operation and/or pre-Fontan cardiac catheterization at Lucile Packard Children's Hospital (LPCH)~Exclusion Criteria:~* Platelet count \< 50K (treprostinil can act as a platelet inhibitor and this may place patient at additional risk of bleeding if already thrombocytopenic)~* Dermatologic condition that renders the patient unable to tolerate a subcutaneous infusion (can still take part in inhaled vasodilator testing during cardiac catheterization)~* Currently receiving any vasodilator therapy specifically for the purpose of pulmonary vasodilation (phosphodiesterase type 5 inhibitor, endothelia receptor antagonist and/or prostacyclin).

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Treprostinil (Type: EXPERIMENTAL): The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.
- Saline (Type: PLACEBO_COMPARATOR): Saline administration via subcutaneous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years old at the time of informed consent~2. Ability to provide written informed consent and HIPAA authorization~3. Solid organ malignancy with documented bone metastasis by imaging~4. Adequate liver function (serum total bilirubin \<= 3 and AST/ALT \<= 3 times the upper normal limit)~5. Adequate renal function (serum creatinine \<= 2mg/dL)~6. Ability to swallow oral tablets~7. Females of childbearing potential must have a negative pregnancy test \<= 28 days prior to registration. All females of childbearing potential who are sexually active, must agree to use a highly reliable method of contraception to prevent pregnancy. These include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections).~   NOTE: Females are considered of childbearing potential unless they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal (\> 12 months since last menses).~8. Patients are permitted to participate in other clinical trials while participating in this trial.~9. Patients will receive standard of care systemic treatment for underlying solid malignancy as deemed necessary by treating physician.~Exclusion Criteria:~1. No prior history of bisphosphonate ordenosumab use in the past 12 months~2. No history of SRE within past 3 months~   1. Excruciating bone pain requiring RT~  2. Cord compression~  3. Hypercalcemia \[serum calcium \>10.5\]~  4. Pathologic fracture~3. No history of Paget's disease~4. No history of epilepsy/seizures~5. No history of hypotension (defined as resting systolic blood pressure of \< 110 mm Hg or diastolic blood pressure of \< 70 mm Hg) or orthostasis (defined as drop in systolic blood pressure of \>20 mm Hg or increase in HR of \> 20 from supine to standing position).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Guanabenz (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Automated Method for Breast Cancer Detection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be female~* Patient must be 18 years of age or older~* Patient has been recommended for ultrasound core needle biopsy of a suspicious breast lesion~Exclusion Criteria:~* Patients may be excluded for any condition that in the opinion of the investigator may not make it safe to take part (e.g. certain medicines).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fine Needle Aspiration (Type: OTHER): Participants will receive fine needle aspiration (FNA) later read by the cytopathologist and the cartridge. All patients will receive standard of care (Ultrasound-guided core needle biopsy and diagnosis).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Male and female patients, 18 years of age or older, with bacteriologically and radiographically confirmed pulmonary MAC infection who have been treated for their infection for at least 6 months within the previous 2 years, as well as patients with moderate or severe pulmonary disease due to MAC, not previously treated for this infection. Patients with recurrent pulmonary MAC infection after previous successful treatment for pulmonary MAC disease are also eligible.~In addition, various laboratory testing must confirm conditions. Patients cannot be positive for HIV or have an extra-pulmonary (in general, outside of the lungs) infection of MAC. Other preconditions related to health or other conditions exist as factors for inclusion or exclusion from this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy